525
Participants
Start Date
September 3, 2013
Primary Completion Date
April 4, 2016
Study Completion Date
March 27, 2023
Olaparib
Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.
Paclitaxel
IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.
Placebo
Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
Research Site, Taoyuan District
Research Site, Tainan City
Research Site, Seoul
Research Site, Taipei
Research Site, Seongnam-si
Research Site, Daegu
Research Site, Hwasun-gun
Research Site, Kaohsiung Hsien
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Changchun
Research Site, Harbin
Research Site, Shanghai
Research Site, Shanghai
Research Site, Nanjing
Research Site, Nanjing
Research Site, Yangzhou
Research Site, Bengbu
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Hangzhou
Research Site, Nanchang
Research Site, Fuzhou
Research Site, Wanzhou
Research Site, Changsha
Research Site, Changsha
Research Site, Changsha
Research Site, Wuhan
Research Site, Zhengzhou
Research Site, Guangzhou
Research Site, Chengdu
Research Site, Chengdu
Research Site, Ürümqi
Research Site, Chiba
Research Site, Chūōku
Research Site, Fukuoka
Research Site, Kasama-shi
Research Site, Kawasaki-shi
Research Site, Kitaadachi-gun
Research Site, Kōtoku
Research Site, Matsuyama
Research Site, Nagoya
Research Site, Sapporo
Research Site, Sapporo
Research Site, Takatsuki-shi
Research Site, Utsunomiya
Research Site, Yokohama
Research Site, Anyang-si
Research Site, Jeonju
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Taichung
Lead Sponsor
AstraZeneca
INDUSTRY